journal article·2024-09-11

Ototoxicity-Alleviating and Cytoprotective Allomelanin Nanomedicine for Efficient Sensorineural Hearing Loss Treatment

Fengqiu Chen, Qingjun Jiang, Baoying Xu, Yuqi Huang, Ke Xu, Xiaoju Xu, Dehong Yu, Yu Chen, Xueling Wang

Publisher page

Abstract

Sensorineural hearing loss (SNHL) represents a significant clinical challenge, predominantly attributed to oxidative stress-related mechanisms. In this work, we report an innovative antioxidant strategy for mitigating SNHL, utilizing synthetically engineered allomelanin nanoparticles (AMNPs). Empirical evidence elucidates AMNPs’ profound capability in free radical neutralization, substantiated by a significant decrement in reactive oxygen species (ROS) levels within HEI-OC1 auditory cells exposure to cisplatin or hydrogen peroxide (H 2 O 2 ). Comparative analyses reveal that AMNPs afford protection against cisplatin-induced and noise-induced auditory impairments, mirroring the effect of dexamethasone (DEX), a standard pharmacological treatment for acute SNHL. AMNPs exhibit notable cytoprotective properties for auditory hair cells (HCs), effectively preventing ototoxicity from cisplatin or H 2 O 2 exposure, as confirmed by both in vitro assays and cultured organ of Corti studies. Further in vivo research corroborates AMNPs’ ability to reverse auditory brainstem response (ABR) threshold shifts resulting from acoustic injury, concurrently reducing HCs loss, ribbon synapse depletion, and spiral ganglion neuron degeneration. The therapeutic benefits of AMNPs are attributed to mitigating oxidative stress and inflammation within the cochlea, with transcriptome analysis indicating downregulated gene expression related to these processes post-AMNPs treatment. The pronounced antioxidative and anti-inflammatory effects of AMNPs position them as a promising alternative to DEX for SNHL treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Vestibular and auditory disorders · Advanced Nanomaterials in Catalysis · Neuroinflammation and Neurodegeneration Mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Otolaryngology-Head and Neck Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200100, China

Materdicine Lab, School of Life Sciences, Shanghai University, Shanghai 200444, China

Funding

Natural Science Foundation of Shanghai Municipality · School of Medicine, Shanghai Jiao Tong University · Shanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases · National Natural Science Foundation of China

References (50)

Show source-provided references
1. World Health Organization. Deafness and Hearing Loss https://www.who.int/, 2023.
2. 10.3390/ijms2211564710.3390/ijms22115647 ↗
3. 10.1007/s10162-013-0374-310.1007/s10162-013-0374-3 ↗
4. 10.1016/j.heares.2023.10878310.1016/j.heares.2023.108783 ↗
5. 10.1016/j.biopha.2022.11404510.1016/j.biopha.2022.114045 ↗
6. 10.3390/jcm1206234710.3390/jcm12062347 ↗
7. 10.7150/thno.8338310.7150/thno.83383 ↗
8. 10.1155/2021/478438510.1155/2021/4784385 ↗
9. 10.1016/j.freeradbiomed.2019.02.02210.1016/j.freeradbiomed.2019.02.022 ↗
10. 10.3390/antiox1012191910.3390/antiox10121919 ↗
11. 10.1016/j.cub.2014.03.03410.1016/j.cub.2014.03.034 ↗
12. 10.1155/2018/317080110.1155/2018/3170801 ↗
13. 10.3389/fphar.2020.0099910.3389/fphar.2020.00999 ↗
14. 10.3390/antiox911107610.3390/antiox9111076 ↗
15. 10.5114/aoms/10912610.5114/aoms/109126 ↗
16. 10.1007/s40272-022-00550-x10.1007/s40272-022-00550-x ↗
17. 10.1097/01.naj.0000911520.74290.b010.1097/01.naj.0000911520.74290.b0 ↗
18. 10.1021/acsami.0c2115110.1021/acsami.0c21151 ↗
19. 10.1186/s12951-020-00600-x10.1186/s12951-020-00600-x ↗
20. 10.1021/acsami.1c0302710.1021/acsami.1c03027 ↗
21. 10.7150/thno.7083010.7150/thno.70830 ↗
22. 10.1016/j.biomaterials.2022.12190410.1016/j.biomaterials.2022.121904 ↗
23. 10.2147/IJN.S9762210.2147/IJN.S97622 ↗
24. 10.3389/fphar.2022.88511310.3389/fphar.2022.885113 ↗
25. 10.1038/s41467-020-16544-710.1038/s41467-020-16544-7 ↗
26. 10.3390/antiox1104079110.3390/antiox11040791 ↗
27. 10.1016/j.actbio.2020.01.04410.1016/j.actbio.2020.01.044 ↗
28. 10.3390/nano1011227610.3390/nano10112276 ↗
29. 10.3390/antiox1204086310.3390/antiox12040863 ↗
30. 10.1016/j.biocel.2021.10614110.1016/j.biocel.2021.106141 ↗
31. 10.3390/pharmaceutics1311185010.3390/pharmaceutics13111850 ↗
32. 10.1186/s12951-021-01199-310.1186/s12951-021-01199-3 ↗
33. 10.1002/cplu.20190019510.1002/cplu.201900195 ↗
34. 10.1007/s00253-020-10532-z10.1007/s00253-020-10532-z ↗
35. 10.1016/j.fbr.2016.12.00310.1016/j.fbr.2016.12.003 ↗
36. 10.1056/EVIDoa230017210.1056/EVIDoa2300172 ↗
37. 10.1038/s41598-019-49133-w10.1038/s41598-019-49133-w ↗
38. 10.1016/j.nantod.2022.10158910.1016/j.nantod.2022.101589 ↗
39. 10.1021/acsnano.9b0216010.1021/acsnano.9b02160 ↗
40. 10.1523/JNEUROSCI.2672-20.202110.1523/JNEUROSCI.2672-20.2021 ↗
41. 10.3390/antiox901002410.3390/antiox9010024 ↗
42. 10.1016/j.redox.2019.10140610.1016/j.redox.2019.101406 ↗
43. 10.1021/jacs.6b1101310.1021/jacs.6b11013 ↗
44. 10.1126/scitranslmed.aao093510.1126/scitranslmed.aao0935 ↗
45. 10.3389/fphar.2023.120714110.3389/fphar.2023.1207141 ↗
46. 10.1016/j.jconrel.2023.11.00710.1016/j.jconrel.2023.11.007 ↗
47. 10.1016/j.nbd.2023.10628010.1016/j.nbd.2023.106280 ↗
48. 10.1121/1.513254510.1121/1.5132545 ↗
49. 10.1016/j.cell.2022.09.02310.1016/j.cell.2022.09.023 ↗
50. 10.1038/s41392-021-00687-010.1038/s41392-021-00687-0 ↗